This study looks into the effects of a combination treatment using cabozantinib and enfortumab vedotin for advanced urothelial cancer. Urothelial cancer affects the bladder and surrounding areas. Cabozantinib may help stop cancer cells from growing by blocking certain proteins. Enfortumab vedotin is a special drug that finds and attacks cancer cells. The trial aims to determine the best dose and understand any benefits or side effects.

Key Points:

• This study involves taking cabozantinib pills daily and enfortumab vedotin through an IV, repeating every 28 days.
• Participants must have had previous treatments and meet specific health criteria. They will be checked regularly for health and treatment progress.
• After treatment, follow-ups will occur at 30 days and every 12 weeks to ensure safety and health.

If you have advanced urothelial cancer, this study could provide a new treatment option. Evaluate if the schedule and requirements fit your needs, and discuss with your doctor if you are interested.